Dr. Barnes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Boston, MA 02114Phone+1 617-724-4000
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2005 - 2007
University of Illinois College of MedicineClass of 2004
Certifications & Licensure
MA State Medical License 2007 - 2026
NH State Medical License 2024 - 2024
ME State Medical License 2020 - 2021
Clinical Trials
- A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL Start of enrollment: 2014 Jun 01
Publications & Presentations
PubMed
- 36 citationsSodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.Carlos A Gongora, Zsofia D Drobni, Thiago Quinaglia Araujo Costa Silva, Amna Zafar, Jingyi Gong
JACC. Heart Failure. 2022-08-01 - 68 citationsPrimary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelinesNeha Mehta-Shah, Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai, Jeffrey A. Barnes
Journal of the National Comprehensive Cancer Network. 2020-05-01 - 34 citationsBrentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.Jeremy S. Abramson, Jon E. Arnason, Ann S. LaCasce, Robert A. Redd, Jeffrey A. Barnes
Blood. 2019-08-15
Abstracts/Posters
- Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD EvaluationJeffrey A. Barnes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)Jeffrey A. Barnes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
